Posts

A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain.

Authors: Barth Wilsey, Thomas Marcotte, Alexander Tsodikov, Jeanna Millman, Heather Bentley, et al
The Journal of Pain, June 2008

The Food and Drug Administration (FDA), Substance Abuse and Mental Health Services Administration (SAMHSA), and the National Institute for Drug Abuse (NIDA) report that no sound scientific studies support the medicinal use of cannabis. Despite this lack of scientific validatio…

Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring.

Authors: Vincent Maida, Marguerite Ennis, Shiraz Irani, Mario Corbo, Michael Dolzhykov
Journal of Supportive Oncology, March 2008

A prospective observational study assessed the effectiveness of adjuvant nabilone (Cesamet) therapy in managing pain and symptoms experienced by advanced cancer patients. The primary outcomes were the differences between treated and untreated patients at 30 days’ follow-up, in…

A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting.

Authors: Mark A Ware, Paul Daeninck, Vincent Maida
Therapeutics and Clinical Risk Management, February 2008

Chemotherapy-induced nausea and vomiting (CINV) in cancer patients places a significant burden on patients’ function and quality of life, their families and caregivers, and healthcare providers. Despite the advances in preventing CINV, a substantial proportion of patients expe…

Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine.

Authors: Ethan B. Russo, Geoffrey W. Guy, Philip J. Robson
Chemistry & Biodiversity, August 2007

Cannabis sativa L. has been utilized for treatment of pain and sleep disorders since ancient times. This review examines modern studies on effects of Delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on sleep. It goes on to report new information on the effects on sleep…

Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis.

Authors: D. R. Blake, P. Robson, M. Ho, R. W. Jubb, C. S. McCabe
Rheumatology, January 2006

OBJECTIVES: To assess the efficacy of a cannabis-based medicine (CBM) in the treatment of pain due to rheumatoid arthritis (RA). METHODS: We compared a CBM (Sativex) with placebo in a randomized, double-blind, parallel group study in 58 patients over 5 weeks of treatment. The…

Pain measurements and side effect profile of the novel cannabinoid ajulemic acid.

Authors: Kahlid Salim, Udo Schneider, Sumner Burstein, Ludwig Hoy, Matthias Karst
Neuropharmacology, June 2005

Preclinical findings on ajulemic acid (AJA) showed analgesic and anti-allodynic effects without psychoactive properties making it an appealing substance for the treatment of pain. A recently published randomized double-blind crossover clinical trial described the pain-reducing…

Cannabinoids and brain injury: therapeutic implications.

Authors: Raphael Mechoulam, David Panikashvili, Esther Shohami
Trends in Molecular Medicine, February 2002

Mounting in vitro and in vivo data suggest that the endocannabinoids anandamide and 2-arachidonoyl glycerol, as well as some plant and synthetic cannabinoids, have neuroprotective effects following brain injury. Cannabinoid receptor agonists inhibit glutamatergic synaptic tran…

Chronic Cannabis Use in the Compassionate Investigational New Drug Program

Authors: Ethan Russo, Mary Lynn Mathre, Al Byrne, Robert Velin, Paul J. Bach, Juan Sanchez-Ramos, et al
Journal of Cannabis Therapeutics, 2002

The Missoula Chronic Clinical Cannabis Use Study was proposed to investigate the therapeutic bepnefits and adverse effects of prolonged use of “medical marijuana” in a cohort of seriously ill patients. Use of cannabis was approved through the Compassionate Inves-tigational New…